Inflammatory Breast Carcinoma (DBCOND0030379)

Identifiers

Synonyms

Breast Inflammatory Carcinoma / Inflammatory breast cancer / Inflammatory carcinoma of the breast / Inflammatory carcinoma of breast (disorder) / Inflammatory Breast Neoplasms / Breast carcinoma inflammatory

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT03598257	Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer	Olaparib	treatment	2	active_not_recruiting
NCT05041101	Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer	AT-001 Eribulin Grapiprant	treatment	1 / 2	terminated
NCT03941756	Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma	Indocyanine green	prevention	Not Available	recruiting
NCT03101748	Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer	Cyclophosphamide Daunorubicin Doxorubicin Neratinib Paclitaxel Pertuzumab Trastuzumab	treatment	1 / 2	active_not_recruiting
NCT05093387	SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer	Carboplatin Pembrolizumab	treatment	1	withdrawn
NCT03012100	Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer	Benzalkonium Cyclophosphamide Folic acid Sargramostim	treatment	2	active_not_recruiting
NCT05177796	Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer	Carboplatin Cyclophosphamide Daunorubicin Doxorubicin Paclitaxel Panitumumab Pembrolizumab	treatment	2	withdrawn
NCT02971748	Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy	Pembrolizumab	treatment	2	active_not_recruiting
NCT00477100	Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients with Inflammatory or Invasive Breast Cancer	No drug interventions	Not Available	Not Available	recruiting
NCT02876107	Carboplatin and Paclitaxel with or Without Panitumumab in Treating Patients with Invasive Triple Negative Breast Cancer	Carboplatin Paclitaxel Panitumumab	treatment	2	active_not_recruiting
NCT03872388	Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy	Atorvastatin Capecitabine	treatment	2	terminated
NCT01730833	Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer	Albumin human Paclitaxel Pertuzumab Trastuzumab	treatment	2	active_not_recruiting
NCT01894451	Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy	Bevacizumab zirconium Zr-89	diagnostic	0	completed
NCT00070252	Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer	Capecitabine Docetaxel Tipifarnib	treatment	1 / 2	completed
NCT01755130	Laser Optoacoustic and Ultrasonic Imaging System Assembly in Finding Changes in Tumors in Patients With Breast Cancer	No drug interventions	diagnostic	Not Available	terminated
NCT02227082	Olaparib and Radiotherapy in Inoperable Breast Cancer	Olaparib	treatment	1	completed
NCT01641406	"Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"	Bevacizumab Capecitabine Cyclophosphamide Docetaxel Epirubicin Trastuzumab Vinorelbine	treatment	2	unknown_status
NCT01038258	Monitoring Response After The First Chemotherapy Cycle After Neoadjuvant Breast Cancer Therapy	No drug interventions	diagnostic	Not Available	unknown_status